← All trials
NCT05727267
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Aug 31, 2025
- First posted
- Feb 14, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of HamburgLead sponsor
- FraunhoferCollaborator
- German Center for Infection ResearchCollaborator
- Helmholtz Centre for Infection ResearchCollaborator
- Monipol Deutschland GmbHCollaborator
- University of HamburgOverall official - principal investigator
- Ludwig Maximilians UniversityCollaborator
- University of HamburgOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.